ArticlePloS one2013
Determination of HER2 amplification status on tumour DNA by digital PCR.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- Review
- Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients.Journal of experimental & clinical cancer research : CR · 2024Article
- Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.NPJ breast cancer · 2024Article
- Liquid biopsy based HER2 amplification status in gastric cancer patients indicates clinical response.Heliyon · 2023Article
- Effect of Antigen Retrieval on Genomic DNA From Immunodissected Samples.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2022Article
- Review
- Detection of KRAS mutations in plasma cell-free DNA of colorectal cancer patients and comparison with cancer panel data for tissue samples of the same cancers.Genomics & informatics · 2019Article
- Principles of digital PCR and its applications in current obstetrical and gynecological diseases.American journal of translational research · 2019Review
- Circulating cell-free DNA for non-invasive cancer management.Cancer genetics · 2018Review
- Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues.Medical oncology (Northwood, London, England) · 2018Article
- Current and Emerging Applications of Droplet Digital PCR in Oncology.Molecular diagnosis & therapy · 2017Review
- Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis.Scientific reports · 2017Article
- Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.Journal of translational medicine · 2017Article
- HER2 mRNA transcript quantitation in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.Cancer discovery · 2016Article
- Development of NIST standard reference material 2373: Genomic DNA standards for HER2 measurements.Biomolecular detection and quantification · 2016Article
- A Robust Protocol for Using Multiplexed Droplet Digital PCR to Quantify Somatic Copy Number Alterations in Clinical Tissue Specimens.PloS one · 2016Article
- Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.International journal of clinical and experimental pathology · 2014Article
- Droplet digital polymerase chain reaction offers an improvisation over conventional immunohistochemistry and fluorescentSouth Asian journal of cancerArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Determination of the presence of HER2 amplification by quantitative PCR has been challenging, in part due to chromosomal instability and identification of a robust a reference region. We assessed the potential of digital PCR for highly accurate assessment of DNA concentration with EFTUD2 as chromosome 17 reference probe. We assessed a HER2:EFTDU2 ratio by digital PCR assay in the microdissected DNA from 18 HER2 amplified and 58 HER2 non-amplified cancers. The HER2:EFTUD2 ratio had high concordance with conventionally defined HER2 status with a sensitivity of 100% (18/18) and a specificity of 98% (57/58). The HER2:EFTUD2 digital PCR assay has potential to accurately assess HER2 amplification status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.